Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William P Tew

Showing results (31-40 of 119) with videos related to

Pageof 12
Sort By:
Gynecologic Oncology|November 24, 2012
Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancerKarin K Shih, Sarah A Milgrom, Nadeem R Abu-Rustum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 22, 2026
Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancerMatthew L Flint, Anna Shvygin, Paul Johannet, et al.
BMC Women'S Health|October 29, 2021
Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative studyDana Ketcher, Susan K Lutgendorf, Susan Leighton, et al.
Investigational New Drugs|October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumorsAndrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Gynecologic Oncology|June 17, 2008
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerJason Konner, Russell J Schilder, Felicia A DeRosa, et al.
Gynecologic Oncology|September 9, 2008
Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapyOliver Zivanovic, Kaled M Alektiar, Yukio Sonoda, et al.
Journal of the American Geriatrics Society|February 6, 2023
Development and implementation of an interdisciplinary telemedicine clinic for older patients with cancer-Preliminary dataKoshy Alexander, Paul A Hamlin, William P Tew, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 24, 2013
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignanciesVaagn Andikyan, Fady Khoury-Collado, Samith Sandadi, et al.
Gynecologic Oncology|September 5, 2018
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group studyWilliam P Tew, Michael W Sill, Joan L Walker, et al.
Gynecologic Oncology|March 28, 2021
Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancerOlga T Filippova, Amy L Tin, Joanne Alonso, et al.
Pageof 12

Showing results (31-40 of 119) with videos related to

Sort By:
Pageof 12
Gynecologic Oncology|November 24, 2012
Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancerKarin K Shih, Sarah A Milgrom, Nadeem R Abu-Rustum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 22, 2026
Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancerMatthew L Flint, Anna Shvygin, Paul Johannet, et al.
BMC Women'S Health|October 29, 2021
Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative studyDana Ketcher, Susan K Lutgendorf, Susan Leighton, et al.
Investigational New Drugs|October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumorsAndrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Gynecologic Oncology|June 17, 2008
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerJason Konner, Russell J Schilder, Felicia A DeRosa, et al.
Gynecologic Oncology|September 9, 2008
Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapyOliver Zivanovic, Kaled M Alektiar, Yukio Sonoda, et al.
Journal of the American Geriatrics Society|February 6, 2023
Development and implementation of an interdisciplinary telemedicine clinic for older patients with cancer-Preliminary dataKoshy Alexander, Paul A Hamlin, William P Tew, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 24, 2013
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignanciesVaagn Andikyan, Fady Khoury-Collado, Samith Sandadi, et al.
Gynecologic Oncology|September 5, 2018
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group studyWilliam P Tew, Michael W Sill, Joan L Walker, et al.
Gynecologic Oncology|March 28, 2021
Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancerOlga T Filippova, Amy L Tin, Joanne Alonso, et al.
Pageof 12